Bibliografía del artículo
1. NIH Technology Assessment Panel on Gaucher's Disease. Gaucher disease: current issues in diagnosis and treatment. JAMA 275:548-53, 1996.
2. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher's disease. Semin Hematol 41(Suppl.2):4-14, 2004.
3. Pastores GM, Einhorn TA. Skeletal complications of Gaucher's disease: pathophysiology, evaluation, and treatment. Seminar in Hematology 32(3) Suppl.A:20-27, 1995.
4. Rademakers RP. Radiologic evaluation of Gaucher's bone disease. Seminars in Hematology 32(3) Suppl.1:14-19, 1995.
5. Maas M, Poll LW,Terk MR. Imaging and quantifying skeletal involvement in Gaucher's disease. The British Journal of Radiology (Suppl.1):A13-24, 2002.
6. Wenstrup RJ, Roca Espiau M, Weinreb NJ, et al. Skeletal aspects of Gaucher disease: a review. Br J Radiol 75(Suppl.1):A2- A12, 2002.
7. Lutsky KF, Tejwani NC. Orthopaedic manifestations of Gaucher disease. Bulletin of the NYU Hospital for Joint Disease 65(1):37-42, 2007.
8. Mankin H, Rosenthal DI, Xavier R. Currents concepts review: Gaucher disease. The Journal of Bone & Joint Surgery 83 A:N 5, 2001.
9. Von Dahl S, Poll L, Di Rocco M, et al. Evidence-based recommendations for monitoring boen disease and the resonance to enzyme replacement therapy in Gaucher patients. Current Medical Research and Opinions 22(6):1045-1064, 2006.
10. Rosenthal DI, Barton NW, McKusick KA, et al. Quantitative imaging of Gaucher disease. Radiology 185:841-845, 1992.
11. Maas M, Van Kuijk C, Stoker J, et al. Quantification of bone involvement in Gaucher's disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging-initial experience. Radiology 229(2):554-61, 2003.
12. Olsen E OE, MaHugh K, Vellodi A. Routine magnetic resonance imaging of the spine in children with Gaucher's disease: does it help therapeutic management? Pediatr Radiol 33(11):782-5, 2003.
13. Charrow J, Anderson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type I Gaucher disease: consensus recommendations The Journal Pediatric January 2004.
14. Grabowski GA, Andria G, Baldellou A, et al. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 163(2):58-66, 2004. Epub 2003 Dec 16.
15. Baldellou A, Andria G, Campbell P, et al. Paediatric non neuronophatic Gaucher disease: recommendations for treatment and monitoring. Eir J Pediatr 2003.
16. Man Z, Oliveri B, Larroude MS, Mastaglia S. Consenso para el diagnóstico, tratamiento y seguimiento de la enfermedad de Gaucher no neuronopática en la República Argentina. Compromiso óseo. Revista Argentina de Osteología 8(2):17-26, 2009.
17. Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type I: Revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 41(Suppl.2):15-22, 2004.
18. Pastores GM, Barnett NL. Current and emerging therapies for the lysosomal storage disorders. Expert Opin Emerg Drugs 10(4):891-902, 2005.
19. Andersson HC, Charrow J, Kaplan P, Mistry P, et al. Individualization long-term enzime replacement therapy for Gaucher disease. Genet Med 7(2):105-110, 2005.
20. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment od Gaucher disease. Seminars in Hematol 41(4) Suppl.5:4-13, 2004.
21. Andersson HC, Charrow J, Kaplan P. et al. Consensus statement by the ICGG US Regional Coordinators on the individualizations of enzyme replacement therapy (ERT) for type I Gaucher disease, 2000.
22. Weinreb NJ, Charrow J, Andersson HC. Et al. Effectiveness of enzyme replacement therapy in 1028 patients with type I Gaucher disease of the 2-5 years of treatment: a report from the Gaucher Registry. Am J Med 113.112-119, 2002.
23. Pastores GM, Patel MJ, Firoozma H, et al. Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2:175-180, 2000.